Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 4/20 | 0.58 |
| ▸ | GABRB2 | P47870 | 4/20 | 0.58 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.58 |
| ▸ | LMNA | P02545 | 3/20 | 0.43 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.43 |
| ▸ | HTR2B | P41595 | 2/20 | 0.43 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.43 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.43 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.43 |
| ▸ | HSP90AA1 | P07900 | 3/20 | 0.43 |
| ▸ | HSP90AB1 | P08238 | 3/20 | 0.43 |
| ▸ | ERN1 | O75460 | 1/20 | 0.42 |
| ▸ | THRB | P10828 | 5/20 | 0.40 |
| ▸ | THRA | P10827 | 4/20 | 0.40 |
| ▸ | CA1 | P00915 | 2/20 | 0.39 |
| ▸ | CA2 | P00918 | 2/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.39 |
| ▸ | FAAH | O00519 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21756935 | 0.82 | LMNA (0.59) | GABRA1GABRB2GABRB1LMNASLC6A2 | |
| SCHEMBL4917919 | 0.81 | RORC (0.58) | GABRA1GABRB2GABRB1LMNASLC6A2 | |
| SCHEMBL12197671 | 0.78 | GABRA1 (0.52) | GABRA1GABRB2GABRB1LMNASLC6A2 | |
| SCHEMBL4395181 | 0.76 | CA1 (0.54) | GABRA1GABRB2GABRB1LMNASLC6A2 | |
| SCHEMBL13818840 | 0.76 | GABRA1 (0.50) | GABRA1GABRB2GABRB1LMNASLC6A2 | |
| SCHEMBL67887 | 0.76 | GABRA1 (0.52) | GABRA1GABRB2GABRB1LMNASLC6A2 | |
| SCHEMBL29457584 | 0.76 | GABRA1 (0.52) | GABRA1GABRB2GABRB1LMNASLC6A2 | |
| Isothymol SCHEMBL852892 | 0.74 | LMNA (0.68) | GABRA1GABRB2GABRB1LMNASLC6A2 | |
| SCHEMBL4647387 | 0.74 | GABRA1 (0.48) | GABRA1GABRB2GABRB1LMNASLC6A2 | |
| Hydroquinone SCHEMBL11207604 | 0.74 | GABRA1 (0.50) | GABRA1GABRB2GABRB1LMNASLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12590072-B2 | Thyromimetics | AUTOBAHN THERAPEUTICS, INC. (US) | 2026-03-31 | — | — | US | disclosed |
| US-12528761-B2 | Thyromimetics | AUTOBAHN THERAPEUTICS, INC. (US) | 2026-01-20 | — | — | US | disclosed |
| US-12466781-B2 | Thyromimetics | AUTOBAHN THERAPEUTICS, INC. (US) | 2025-11-11 | — | — | US | disclosed |
| US-20240425437-A1 | DERIVATIVES OF SOBETIROME | OREGON HEALTH & SCIENCE UNIVERSITY (US) | 2024-12-26 | — | — | US | disclosed |
| CN-118791364-A | Cycloparaffin intermediate and preparation method of cycloparaffin | 山东百诺医药股份有限公司 | 2024-10-18 | — | — | CN | disclosed |
| CN-118772065-A | Preparation method of gefarnesyl key intermediate | 上海工程技术大学 | 2024-10-15 | — | — | CN | disclosed |
| US-20230348364-A1 | ISOTOPIC THYROMIMETIC COMPOUNDS | AUTOBAHN THERAPEUTICS, INC. | 2023-11-02 | — | — | US | disclosed |
| US-20230242473-A1 | THYROMIMETICS | AUTOBAHN THERAPEUTICS, INC. | 2023-08-03 | — | — | US | disclosed |
| US-20230242473-A1 | THYROMIMETICS | AUTOBAHN THERAPEUTICS, INC. | 2023-08-03 | — | — | US | disclosed |
| US-20230242492-A1 | THYROMIMETICS | AUTOBAHN THERAPEUTICS, INC. | 2023-08-03 | — | — | US | disclosed |
| US-9701650-B2 | Derivatives of sobetirome | OREGON HEALTH & SCIENCE UNIVERSITY (US) | 2017-07-11 | — | — | US | disclosed |
| US-9643934-B2 | Process for synthesis of phenoxy diaminopyrimidine derivatives | ROCHE PALO ALTO LLC (US) | 2017-05-09 | — | — | US | disclosed |
| WO-2016174551-A1 | ANTI-ESTROGENIC COMPOUNDS | PFIZER INC. (US) | 2016-11-03 | — | — | WO | disclosed |
| WO-2016134292-A1 | DERIVATIVES OF SOBETIROME | OREGON HEALTH & SCIENCE UNIVERSITY (US) | 2016-08-25 | — | — | WO | disclosed |
| US-20160244418-A1 | DERIVATIVES OF SOBETIROME | OREGON HEALTH & SCIENCE UNIVERSITY (US) | 2016-08-25 | — | — | US | disclosed |
| CN-102906129-B | Process for selectively polymerizing ethylene and catalyst therefor | DOW GLOBAL TECHNOLOGIES LLC | 2015-02-25 | — | — | CN | disclosed |
| US-20080312339-A1 | FLUORINE-SUBSTITUTED ALKYL PHENOL COMPOUNDS AND THEIR USES | BAKER MAX T | 2008-12-18 | — | — | US | disclosed |
| US-7312250-B2 | Fluorine-substituted alkyl phenol compounds and their uses | UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) | 2007-12-25 | — | — | US | disclosed |
| WO-2003077894-A1 | FLUORINE-SUBSTITUTED ALKYL PHENOL COMPOUNDS AND THEIR USES | UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) | 2003-09-25 | — | — | WO | disclosed |
| US-20030176513-A1 | Fluorine-substituted alkyl phenol compounds and their uses | IOWA RESEARCH FOUNDATION, UNIVERSITY OF | 2003-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030176513-A1 | Fluorine-substituted alkyl phenol compounds and their uses | AFF4, AFF1, AFF2 | GABRA1 3412/4885GABRB2 4004/4885GABRB1 3961/4885 |
| US-20230348364-A1 | ISOTOPIC THYROMIMETIC COMPOUNDS | TPO, THOP1, TSHR | GABRA1 1858/4885GABRB2 1806/4885GABRB1 1591/4885 |
| US-20230242492-A1 | THYROMIMETICS | TPO, TSHR, THOP1 | GABRA1 3232/4885GABRB2 2645/4885GABRB1 2473/4885 |
| US-12466781-B2 | Thyromimetics | TPO, TSHR, CHRM1 | GABRA1 3097/4885GABRB2 3634/4885GABRB1 3157/4885 |
| US-20160244418-A1 | DERIVATIVES OF SOBETIROME | SLC18A2, SLC6A2, SLC6A4 | GABRA1 26/4885GABRB2 19/4885GABRB1 25/4885 |
| US-20080312339-A1 | FLUORINE-SUBSTITUTED ALKYL PHENOL COMPOUNDS AND THEIR USES | AFF4, AFF1, AFF2 | GABRA1 3412/4885GABRB2 4004/4885GABRB1 3961/4885 |
| US-12590072-B2 | Thyromimetics | THRB, TSHR, TRHR | GABRA1 1420/4885GABRB2 1103/4885GABRB1 864/4885 |
| US-20240425437-A1 | DERIVATIVES OF SOBETIROME | SNCA, SLC6A3, SLC6A1 | GABRA1 16/4885GABRB2 22/4885GABRB1 26/4885 |
| US-20230242473-A1 | THYROMIMETICS | TPO, THOP1, THRB | GABRA1 3072/4885GABRB2 2478/4885GABRB1 2216/4885 |
| US-12528761-B2 | Thyromimetics | TSHR, THRB, TTR | GABRA1 1488/4885GABRB2 1430/4885GABRB1 960/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.